| 0 (0%) | 04-19 14:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.79 | 1-year : | 2.09 |
| Resists | First : | 1.53 | Second : | 1.79 |
| Pivot price | 1.41 |
|||
| Supports | First : | 1.39 | Second : | 1.3 |
| MAs | MA(5) : | 1.48 |
MA(20) : | 1.39 |
| MA(100) : | 1.55  |
MA(250) : | 2.12 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.5 | D(3) : | 77.5 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 3.16 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PVL ] has closed below upper band by 21.7%. Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.42 - 1.43 | 1.43 - 1.44 |
| Close: | 1.45 - 1.46 | 1.46 - 1.47 |
Fri, 12 Apr 2024
Hoodie Outfits For Girls Cheap Sale | atlantaprogressivenews.com - Atlanta Progressive News
Fri, 22 Jan 2021
Lilly Completes Acquisition of Prevail Therapeutics | Eli Lilly and Company - Investors | Eli Lilly and Company
Thu, 21 Jan 2021
Prevail Therapeutics Shareholders Are Getting A Big Contingent Value Right (NASDAQ:PRVL-DEFUNCT-599268) - Seeking Alpha
Tue, 15 Dec 2020
Prevail Therapeutics Stock Surges After Eli Lilly Acquisition Announcement - AskTraders
Tue, 15 Dec 2020
Lilly Announces Agreement to Acquire Prevail Therapeutics | Eli Lilly and Company - Investors | Eli Lilly and Company
Mon, 23 Dec 2019
IPO's to focus on today (AKRO, BCEL, PRVL, PSNL, GO, CMBM) - BP Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 33 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 27.5 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.55 |
| Profit Margin | 135.5 % |
| Operating Margin | 75 % |
| Return on Assets (ttm) | 10.5 % |
| Return on Equity (ttm) | 25.1 % |
| Qtrly Rev. Growth | -90.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 3.44 |
| PEG Ratio | 0 |
| Price to Book value | 0.94 |
| Price to Sales | 4.69 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|